Microbiome As a Biomarker and Therapeutic Target in Pancreatic Cancer Publisher Pubmed

Summary: Review suggests microbiome as a biomarker and therapy target for pancreatic cancer treatment. #PancreaticCancer #Microbiome

Pourali G¹ ; Kazemi D² ; Chadeganipour AS⁹ ; Arastonejad M³ ; Kashani SN¹ ; Pourali R⁴ ; Maftooh M¹ ; Akbarzade H¹ ; Fiuji H⁵ ; Hassanian SM^{1, 5} ; Ghayourmobarhan M¹ ; Ferns GA⁶ ; Khazaei M^{1, 5} ; Avan A^{1, 7, 8}
Source: BMC Microbiology Published:2024

Abstract

Studying the effects of the microbiome on the development of different types of cancer has recently received increasing research attention. In this context, the microbial content of organs of the gastrointestinal tract has been proposed to play a potential role in the development of pancreatic cancer (PC). Proposed mechanisms for the pathogenesis of PC include persistent inflammation caused by microbiota leading to an impairment of antitumor immune surveillance and altered cellular processes in the tumor microenvironment. The limited available diagnostic markers that can currently be used for screening suggest the importance of microbial composition as a non-invasive biomarker that can be used in clinical settings. Samples including saliva, stool, and blood can be analyzed by 16 s rRNA sequencing to determine the relative abundance of specific bacteria. Studies have shown the potentially beneficial effects of prebiotics, probiotics, antibiotics, fecal microbial transplantation, and bacteriophage therapy in altering microbial diversity, and subsequently improving treatment outcomes. In this review, we summarize the potential impact of the microbiome in the pathogenesis of PC, and the role these microorganisms might play as biomarkers in the diagnosis and determining the prognosis of patients. We also discuss novel treatment methods being used to minimize or prevent the progression of dysbiosis by modulating the microbial composition. Emerging evidence is supportive of applying these findings to improve current therapeutic strategies employed in the treatment of PC. © 2023, The Author(s).